ALT Q3 2020 Earnings — Altimmune, Inc. Revenue & Financial Results | Market Cap Arena

ALTAltimmune, Inc.

$331M

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+356.2% YoY

Gross Profit

$3M100.0% margin

Operating Income

-$18M-623.7% margin

Net Income

-$18M-604.8% margin

EPS (Diluted)

$-0.54

QoQ Revenue Growth

+307.1%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$233M

Total Liabilities

$33M

Stockholders' Equity

$200M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$643,978	+356.2%
Gross Profit	$3M	-$8M	+136.3%
Operating Income	-$18M	-$11M	-62.5%
Net Income	-$18M	-$11M	-62.4%